Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 9/2019

01.09.2019 | Arrhythmia (R Kabra, Section Editor)

Diagnostic and Therapeutic Approach to Arrhythmias in Adult Congenital Heart Disease

verfasst von: Karine Guerrier, DO, MPH, Benjamin Hendrickson, MD, B. Rush Waller, MD, Glenn T. Wetzel, MD, PhD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Adult survivors of congenital heart disease (CHD) are at increased risk of arrhythmia. The goal of this review is to outline diagnostic and therapeutic approaches to arrhythmia in adult CHD patients.

Recent findings

Macro-reentrant atrial tachyarrhythmia is the most common arrhythmia encountered in adults with CHD. Approximately 25% of hospitalizations associated with arrhythmia. The risk of ventricular arrhythmia is estimated as high as 25–100 times that for the general population and increased after two decades.

Summary

Routine ambulatory monitoring is important for arrhythmia risk assessment in adults with CHD. There are limitations, potential adverse effects, and risk of recurrence with antiarrhythmic drugs, catheter ablation, and surgical approaches. Adults with CHD suffer various forms of arrhythmia, are at increased risk of sudden death, and require special consideration for medical and interventional therapy.
Literatur
1.
Webb G, Mulder BJ, Aboulhosn J, Daniels CJ, Elizari MA, Hong G, et al. The care of adults with congenital heart disease across the globe: current assessment and future perspective: a position statement from the International Society for Adult Congenital Heart Disease (ISACHD). Int J Cardiol. 2015;195:326–33.PubMed
2.
Ntiloudi D, Giannakoulas G, Parcharidou D, Panagiotidis T, Gatzoulis MA, Karvounis H. Adult congenital heart disease: a paradigm of epidemiological change. Int J Cardiol. 2016;218:269–74.PubMed
3.
Khairy P, Ionescu-Ittu R, Mackie AS, Abrahamowicz M, Pilote L, Marelli AJ. Changing mortality in congenital heart disease. J Am Coll Cardiol. 2010;56(14):1149–57.PubMed
4.
Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749–56.PubMed
5.
Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, Nembhard WN, et al. Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation. 2016;134(2):101–9.PubMedPubMedCentral
6.
Raskind-Hood C, Hogue C, Overwyk KJ, Book W. Estimates of adolescent and adult congenital heart defect prevalence in metropolitan Atlanta, 2010, using capture-recapture applied to administrative records. Ann Epidemiol. 2019;32:72–7 e72.PubMed
7.
Benziger CP, Stout K, Zaragoza-Macias E, Bertozzi-Villa A, Flaxman AD. Projected growth of the adult congenital heart disease population in the United States to 2050: an integrative systems modeling approach. Popul Health Metrics. 2015;13:29.
8.
Mohan S, Moffett BS, Lam W, de la Uz C, Miyake C, Valdes SO, et al. Analysis of adults with congenital heart disease presenting to pediatric emergency departments with arrhythmias. Congenit Heart Dis. 2017;12(4):507–11.PubMed
9.
Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation. 2007;115(4):534–45.PubMed
10.
Janson CM, Shah MJ. Supraventricular tachycardia in adult congenital heart disease: mechanisms, diagnosis, and clinical aspects. Card Electrophysiol Clin. 2017;9(2):189–211.PubMed
11.
Sathananthan G, Harris L, Nair K. Ventricular arrhythmias in adult congenital heart disease: mechanisms, diagnosis, and clinical aspects. Card Electrophysiol Clin. 2017;9(2):213–23.PubMed
12.
• Moore JP, Aboulhosn JA. Introduction to the congenital heart defects: anatomy of the conduction system. Card Electrophysiol Clin. 2017;9(2):167–75 This article summarizes important variation in conduction system anatomy across the spectrum of congenital heart disease lesions.PubMed
13.
Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm. 2014;11(10):e102–65.PubMed
14.
Bossers SS, Duppen N, Kapusta L, et al. Comprehensive rhythm evaluation in a large contemporary Fontan population. Eur J Cardiothorac Surg. 2015;48(6):833–40 discussion 840-831.PubMed
15.
Lasa JJ, Glatz AC, Daga A, Shah M. Prevalence of arrhythmias late after the Fontan operation. Am J Cardiol. 2014;113(7):1184–8.PubMed
16.
Beauchesne LM, Warnes CA, Connolly HM, Ammash NM, Tajik AJ, Danielson GK. Outcome of the unoperated adult who presents with congenitally corrected transposition of the great arteries. J Am Coll Cardiol. 2002;40(2):285–90.PubMed
17.
Siehr SL, Hanley FL, Reddy VM, Miyake CY, Dubin AM. Incidence and risk factors of complete atrioventricular block after operative ventricular septal defect repair. Congenit Heart Dis. 2014;9(3):211–5.PubMed
18.
Lin A, Mahle WT, Frias PA, Fischbach PS, Kogon BE, Kanter KR, et al. Early and delayed atrioventricular conduction block after routine surgery for congenital heart disease. J Thorac Cardiovasc Surg. 2010;140(1):158–60.PubMed
19.
Anderson JB, Czosek RJ, Knilans TK, Meganathan K, Heaton P. Postoperative heart block in children with common forms of congenital heart disease: results from the KID Database. J Cardiovasc Electrophysiol. 2012;23(12):1349–54.PubMed
20.
Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13(12):2272–8.PubMed
21.
Khairy P, Aboulhosn J, Gurvitz MZ, Opotowsky AR, Mongeon F̧P, Kay J, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation. 2010;122(9):868–75.PubMed
22.
Wasmer K, Kobe J, Dechering DG, et al. Isthmus-dependent right atrial flutter as the leading cause of atrial tachycardias after surgical atrial septal defect repair. Int J Cardiol. 2013;168(3):2447–52.PubMed
23.
Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N, et al. Atrial arrhythmias in adults with congenital heart disease. Circulation. 2009;120(17):1679–86.PubMed
24.
Labombarda F, Hamilton R, Shohoudi A, Aboulhosn J, Broberg CS, Chaix MA, et al. Increasing prevalence of atrial fibrillation and permanent atrial arrhythmias in congenital heart disease. J Am Coll Cardiol. 2017;70(7):857–65.PubMed
25.
Mandalenakis Z, Rosengren A, Lappas G, Eriksson P, Gilljam T, Hansson PO, et al. Atrial fibrillation burden in young patients with congenital heart disease. Circulation. 2018;137(9):928–37.PubMed
26.
Roca-Luque I, Rivas-Gandara N, Subira LD, et al. Mechanisms of intra-atrial re-entrant tachycardias in congenital heart disease: types and predictors. Am J Cardiol. 2018;122(4):672–82.PubMed
27.
Yang H, Kuijpers JM, de Groot JR, Konings TC, van Dijk A, Sieswerda GT, et al. Impact of atrial arrhythmias on outcome in adults with congenital heart disease. Int J Cardiol. 2017;248:152–4.PubMed
28.
Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation. 2007;116(20):2241–52.PubMed
29.
Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998;32(1):245–51.PubMed
30.
Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000;86(10):1111–6.PubMed
31.
Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. Eur Heart J. 2010;31(10):1220–9.PubMed
32.
Naidu P, Grigg L, Zentner D. Mortality in adults with congenital heart disease. Int J Cardiol. 2017;245:125–30.PubMed
33.
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91–e220.PubMed
34.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015;17(11):1601–87.PubMed
35•.
Stout KK, Daniels CJ, Aboulhosn JA, et al. AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(12):1494–1563. This article summarizes disease-specific recommendations regarding surveillance and management of arrhythmia in adults with congenital heart disease.
36.
Moore B, Yu C, Kotchetkova I, Cordina R, Celermajer DS. Incidence and clinical characteristics of sudden cardiac death in adult congenital heart disease. Int J Cardiol. 2018;254:101–6.PubMed
37.
Koyak Z, de Groot JR, Bouma BJ, Zwinderman AH, Silversides CK, Oechslin EN, et al. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace. 2017;19(3):401–6.PubMed
38.
Pundi KN, Pundi KN, Johnson JN, Dearani JA, Li Z, Driscoll DJ, et al. Sudden cardiac death and late arrhythmias after the Fontan operation. Congenit Heart Dis. 2017;12(1):17–23.PubMed
39.
Drakopoulou M, Nashat H, Kempny A, Alonso-Gonzalez R, Swan L, Wort SJ, et al. Arrhythmias in adult patients with congenital heart disease and pulmonary arterial hypertension. Heart. 2018;104(23):1963–9.PubMed
40.
Bezzerides VJ, Walsh A, Martuscello M, Escudero CA, Gauvreau K, Lam G, et al. The real-world utility of the LINQ implantable loop recorder in pediatric and adult congenital heart patients. JACC Clin Electrophysiol. 2019;5(2):245–51.PubMed
41.
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67(13):e27–e115.PubMed
42.
Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993;270(20):2451–5.PubMed
43.
Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.PubMed
44.
Cunningham T, Uzun O, Morris R, Franciosi S, Wong A, Jeremiasen I, et al. The safety and effectiveness of flecainide in children in the current era. Pediatr Cardiol. 2017;38(8):1633–8.PubMed
45.
Moore BM, Cordina RL, McGuire MA, Celermajer DS. Adverse effects of amiodarone therapy in adults with congenital heart disease. Congenit Heart Dis. 2018;13(6):944–51.PubMed
46.
Iwasawa S, Uyeda T, Saito M, Ishii T, Inage A, Hamamichi Y, et al. Efficacy and safety of low-dose amiodarone therapy for tachyarrhythmia in congenital heart disease. Pediatr Cardiol. 2018;39(5):1016–22.PubMed
47.
Moore BM, Cordina RL, McGuire MA, Celermajer DS. Efficacy and adverse effects of sotalol in adults with congenital heart disease. Int J Cardiol. 2019;274:74–9.PubMed
48.
Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol. 2007;30(8):1003–8.PubMed
49.
El-Assaad I, Al-Kindi SG, Abraham J, et al. Use of dofetilide in adult patients with atrial arrhythmias and congenital heart disease: a PACES collaborative study. Heart Rhythm. 2016;13(10):2034–9.PubMed
50.
Kumar S, Tedrow UB, Triedman JK. Arrhythmias in adult congenital heart disease: diagnosis and management. Cardiol Clin. 2015;33(4):571–88 viii.PubMed
51.
Collins KK, Love BA, Walsh EP, Saul JP, Epstein MR, Triedman JK. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease. Am J Cardiol. 2000;86(9):969–74.PubMed
52.
Kanter RJ, Papagiannis J, Carboni MP, Ungerleider RM, Sanders WE, Wharton JM. Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning operations for d-transposition of the great arteries. J Am Coll Cardiol. 2000;35(2):428–41.PubMed
53.
Triedman JK, Alexander ME, Love BA, Collins KK, Berul CI, Bevilacqua LM, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 2002;39(11):1827–35.PubMed
54.
Triedman JK, Bergau DM, Saul JP, Epstein MR, Walsh EP. Efficacy of radiofrequency ablation for control of intraatrial reentrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 1997;30(4):1032–8.PubMed
55.
Lewis M, Whang W, Biviano A, Hickey K, Garan H. Rosenbaum M. Congenit Heart Dis: Predictors and rates of recurrence of atrial arrhythmias following catheter ablation in adults with congenital heart disease; 2018.
56.
Yap SC, Harris L, Downar E, Nanthakumar K, Silversides CK, Chauhan VS. Evolving electroanatomic substrate and intra-atrial reentrant tachycardia late after Fontan surgery. J Cardiovasc Electrophysiol. 2012;23(4):339–45.PubMed
57.
Liang JJ, Frankel DS, Parikh V, et al. Safety and outcomes of catheter ablation for atrial fibrillation in adults with congenital heart disease: a multicenter registry study. Heart Rhythm. 2019;16(6):846–852.PubMed
58.
Roca-Luque I, Rivas-Gandara N, Dos Subira L, et al. Long-term follow-up after ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease: types and predictors of recurrence. JACC Clin Electrophysiol. 2018;4(6):771–80.PubMed
59.
Roca-Luque I, Rivas-Gandara N, Dos-Subira L, et al. Predictors of acute failure ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease: cardiac disease, atypical flutter, and previous atrial fibrillation. J Am Heart Assoc. 2018;7(7).
60.
Grubb CS, Lewis M, Whang W, Biviano A, Hickey K, Rosenbaum M, et al. Catheter ablation for atrial tachycardia in adults with congenital heart disease: electrophysiological predictors of acute procedural success and post-procedure atrial tachycardia recurrence. JACC Clin Electrophysiol. 2019;5(4):438–47.PubMed
61.
Papagiannis J, Beissel DJ, Krause U, et al. Atrioventricular nodal reentrant tachycardia in patients with congenital heart disease: outcome after catheter ablation. Circ Arrhythm Electrophysiol. 2017;10(7).
62.
Upadhyay S, Marie Valente A, Triedman JK, Walsh EP. Catheter ablation for atrioventricular nodal reentrant tachycardia in patients with congenital heart disease. Heart Rhythm. 2016;13(6):1228–37.PubMed
63.
Brouwer C, Hazekamp MG, Zeppenfeld K. Anatomical substrates and ablation of reentrant atrial and ventricular tachycardias in repaired congenital heart disease. Arrhythmia Electrophysiol Rev. 2016;5(2):150–60.
64.
Yang J, Brunnquell M, Liang JJ, Callans DJ, Garcia FC, Lin D, et al. Long term follow up after ventricular tachycardia ablation in patients with congenital heart disease. J Cardiovasc Electrophysiol. 2019;1–9.
65.
Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol. 2015;8(1):102–9.PubMed
66.
van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm. 2016;13(7):1449–54.PubMed
67.
Silka MJ, Manwill JR, Kron J, McAnulty JH. Bradycardia-mediated tachyarrhythmias in congenital heart disease and responses to chronic pacing at physiologic rates. Am J Cardiol. 1990;65(7):488–93.PubMed
68.
Kamp AN, LaPage MJ, Serwer GA, Dick M 2nd, Bradley DJ. Antitachycardia pacemakers in congenital heart disease. Congenit Heart Dis. 2015;10(2):180–4.PubMed
69.
Kramer CC, Maldonado JR, Olson MD, Gingerich JC, Ochoa LA, Law IH. Safety and efficacy of atrial antitachycardia pacing in congenital heart disease. Heart Rhythm. 2018;15(4):543–7.PubMed
70.
Acosta H, Viafara LM, Izquierdo D, Pothula VR, Bear J, Pothula S, et al. Atrial lead placement at the lower atrial septum: a potential strategy to reduce unnecessary right ventricular pacing. Europace. 2012;14(9):1311–6.PubMed
71.
Janousek J. Device therapy in children with and without congenital heart disease. Herzschrittmacherther Elektrophysiol. 2014;25(3):183–7.PubMed
72.
Janousek J, van Geldorp IE, Krupickova S, et al. Permanent cardiac pacing in children: choosing the optimal pacing site: a multicenter study. Circulation. 2013;127(5):613–23.PubMed
73.
Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126(16):1944–54.PubMed
74.
Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008;117(3):363–70.PubMed
75.
Khairy P, Landzberg MJ, Gatzoulis MA, Mercier LA, Fernandes SM, Côté JM, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation. 2006;113(20):2391–7.PubMed
76.
Groh CA, Sharma S, Pelchovitz DJ, Bhave PD, Rhyner J, Verma N, et al. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014;11(8):1361–6.PubMed
77.
Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol. 2014;25(5):494–9.PubMed
78.
Garside H, Leyva F, Hudsmith L, Marshall H, de Bono J. Eligibility for subcutaneous implantable cardioverter defibrillators in the adult congenital heart disease population. Pacing Clin Electrophysiol. 2019;42(1):65–70.PubMed
79.
Zeb M, Curzen N, Veldtman G, Yue A, Roberts P, Wilson D, et al. Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping. Europace. 2015;17(7):1059–67.PubMed
80.
Okamura H, McLeod CJ, DeSimone CV, et al. Right parasternal lead placement increases eligibility for subcutaneous implantable cardioverter defibrillator therapy in adults with congenital heart disease. Circ J. 2016;80(6):1328–35.PubMed
81.
Santharam S, Hudsmith L, Thorne S, Clift P, Marshall H, De Bono J. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes. Europace. 2017;19(3):407–13.PubMed
82.
Hayward RM, Dewland TA, Moyers B, Vittinghoff E, Tanel RE, Marcus GM, et al. Device complications in adult congenital heart disease. Heart Rhythm. 2015;12(2):338–44.PubMed
83.
Midha D, Chen Z, Jones DG, Williams HJ, Lascelles K, Jarman J, et al. Pacing in congenital heart disease - a four-decade experience in a single tertiary centre. Int J Cardiol. 2017;241:177–81.PubMed
84.
Fender EA, Killu AM, Cannon BC, Friedman PA, Mcleod CJ, Hodge DO, et al. Lead extraction outcomes in patients with congenital heart disease. Europace. 2017;19(3):441–6.PubMed
85.
Wazni O, Epstein LM, Carrillo RG, Love C, Adler SW, Riggio DW, et al. Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol. 2010;55(6):579–86.PubMed
86.
Shepherd E, Stuart G, Martin R, Walsh MA. Extraction of SelectSecure leads compared to conventional pacing leads in patients with congenital heart disease and congenital atrioventricular block. Heart Rhythm. 2015;12(6):1227–32.PubMed
87.
Garnreiter J, Whitaker P, Pilcher T, Etheridge S, Saarel E. Lumenless pacing leads: performance and extraction in pediatrics and congenital heart disease. Pacing Clin Electrophysiol. 2015;38(1):42–7.PubMed
88.
Gourraud JB, Chaix MA, Shohoudi A, et al. Transvenous lead extraction in adults with congenital heart disease: insights from a 20-year single-center experience. Circ Arrhythm Electrophysiol. 2018;11(2):e005409.PubMed
89.
Bedair R, Babu-Narayan SV, Dimopoulos K, Quyam S, Doyle AM, Swan L, et al. Acceptance and psychological impact of implantable defibrillators amongst adults with congenital heart disease. Int J Cardiol. 2015;181:218–24.PubMed
90.
Cook SC, Valente AM, Maul TM, et al. Shock-related anxiety and sexual function in adults with congenital heart disease and implantable cardioverter-defibrillators. Heart Rhythm. 2013;10(6):805–10.PubMed
91.
Mavroudis C, Deal BJ. Prophylactic arrhythmia surgery in association with congenital heart disease. Transl Pediatr. 2016;5(3):148–59.PubMedPubMedCentral
92.
Mavroudis C, Deal B, Backer CL, Stewart RD. Operative techniques in association with arrhythmia surgery in patients with congenital heart disease. World J Pediatr Congenit Heart Surg. 2013;4(1):85–97.PubMed
93.
Uemura H. Surgical aspects of atrial arrhythmia : right atrial ablation and anti-arrhythmic surgery in congenital heart disease. Herzschrittmacherther Elektrophysiol. 2016;27(2):137–42.PubMed
94.
Cox JL. Cardiac surgery for arrhythmias. Heart Rhythm. 2004;1(5 Suppl):85C–101C.PubMed
95.
Lawrance CP, Henn MC, Damiano RJ Jr. Surgery for atrial fibrillation. Heart Fail Clin. 2016;12(2):235–43.PubMed
96.
Deal BJ, Mavroudis C. Arrhythmia surgery for adults with congenital heart disease. Card Electrophysiol Clin. 2017;9(2):329–40.PubMed
97.
Mavroudis C, Stulak JM, Ad N, Siegel A, Giamberti A, Harris L, et al. Prophylactic atrial arrhythmia surgical procedures with congenital heart operations: review and recommendations. Ann Thorac Surg. 2015;99(1):352–9.PubMed
98.
Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and the Cox-maze procedure in congenital heart disease. Congenit Heart Dis. 2013;8(5):434–9.PubMed
99.
Gonzalez Corcia MC, Walsh EP. Emani S. Europace: Long-term results of atrial maze surgery in patients with congenital heart disease; 2019.
100.
Ramdjan T, Mouws E, Kik C, Roos-Hesselink JW, Bogers A, de Groot NMS. Concomitant arrhythmia surgery in patients with congenital heart disease. Interact Cardiovasc Thorac Surg. 2018;27(6):902–9.PubMed
101.
Sakamoto SI, Hiromoto A, Ishii Y, Sasaki T, Miyagi Y, Nitta T. Surgical outcomes of modified-maze procedures in adults with atrial septal defect. Surg Today. 2019;49(2):124–9.PubMed
102.
Giamberti A, Pluchinotta FR, Chessa M, et al. Surgery for supraventricular tachycardia and congenital heart defects: long-term efficacy of the combined approach in adult patients. Europace. 2017;19(9):1542–8.PubMed
103.
Deal BJ, Costello JM, Webster G, Tsao S, Backer CL, Mavroudis C. Intermediate-term outcome of 140 consecutive Fontan conversions with arrhythmia operations. Ann Thorac Surg. 2016;101(2):717–24.PubMed
104.
Sandhu A, Ruckdeschel E, Sauer WH, Collins KK, Kay JD, Khanna A, et al. Perioperative electrophysiology study in patients with tetralogy of Fallot undergoing pulmonary valve replacement will identify those at high risk of subsequent ventricular tachycardia. Heart Rhythm. 2018;15(5):679–85.PubMed
105.
Caldaroni F, Lo Rito M, Chessa M, et al. Surgical ablation of ventricular tachycardia in patients with repaired tetralogy of Fallot. Eur J Cardiothorac Surg. 2019;55(5):845–850.
Metadaten
Titel
Diagnostic and Therapeutic Approach to Arrhythmias in Adult Congenital Heart Disease
verfasst von
Karine Guerrier, DO, MPH
Benjamin Hendrickson, MD
B. Rush Waller, MD
Glenn T. Wetzel, MD, PhD
Publikationsdatum
01.09.2019
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 9/2019
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-019-0749-9

Weitere Artikel der Ausgabe 9/2019

Current Treatment Options in Cardiovascular Medicine 9/2019 Zur Ausgabe

Arrhythmia (R Kabra, Section Editor)

Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death

Heart Failure (W Tang, Section Editor)

How to Optimize Patient Selection and Device Performance of the Newest Generation Left Ventricular Assist Devices

Heart Failure (W Tang, Section Editor)

CRT Optimization: What Is New? What Is Necessary?

Arrhythmia (R Kabra, Section Editor)

Atrial Fibrillation Ablation: Indications and Techniques

Pregnancy and Cardiovascular Disease (N Scott, Section Editor)

Maternal Mortality in the United States and the HOPE Registry

Arrhythmia (R Kabra, Section Editor)

Impact of Technique and Technology on Mitral Isthmus Ablation

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise